8,385 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Convergence Investment Partners LLC

Convergence Investment Partners LLC bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 8,385 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,033,000.

Several other hedge funds have also made changes to their positions in the company. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after buying an additional 278,465 shares during the period. Cinctive Capital Management LP purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at about $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Jazz Pharmaceuticals by 47.7% during the third quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock valued at $29,945,000 after purchasing an additional 86,768 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Jazz Pharmaceuticals by 393.0% in the 3rd quarter. Two Sigma Advisers LP now owns 106,000 shares of the specialty pharmaceutical company’s stock valued at $11,809,000 after acquiring an additional 84,500 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 0.3 %

JAZZ stock opened at $134.96 on Thursday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $138.27. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm’s fifty day moving average is $124.32 and its 200 day moving average is $117.68. The firm has a market cap of $8.16 billion, a PE ratio of 19.01, a P/E/G ratio of 1.02 and a beta of 0.56.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JAZZ. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC restated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.